BIO-TECHNE Corp 4

Steven C. Crouse, President - Diagnostic & Spatial Biology of Bio-Techne Corp, was awarded a total of 22,842 restricted stock units of common stock on August 17, 2026 as part of equity compensation grants.

On August 17, 2026, Bio-Techne Corp executive Steven C. Crouse (President - Diagnostic & Spatial Biology) received equity compensation awards consisting of 8,702 restricted stock units (including performance RSUs) and a separate grant of 14,140 time-based restricted stock units, each unit representing a contingent right to one share of common stock. The filing also discloses his existing option and RSU inventory with various exercise prices and long-dated expirations, as well as detailed future vesting schedules for both stock options and RSUs through 2029, indicating this is a routine annual equity grant rather than an open-market transaction. No purchases or sales of common stock for cash occurred; instead, the transaction reflects the company’s long-term incentive compensation program, leaving Crouse with 8,702 RSUs and 14,140 additional RSUs reported as beneficially owned following these grants, with total dollar value not directly determinable from the filing due to the absence of a contemporaneous market price.

Filing Facts

CIK

842023

Ticker

TECH

Form

4

Source Type

fda

Accession

0000914190-26-000129

Alert Tier

6